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increase in the total search yield were retained. Supple-
mental electronic (Current Contents, Cochrane, Univer-
sity of York NHS Centre) and manual searches were used
to create a listing of accepted studies for comparison to
the PubMed-only search results. RESULTS: Three thou-
sand six hundred seventy-seven citations were down-
loaded and screened from all sources, resulting in 135
accepted papers across the ﬁve settings (asthma-20,
depression-40, diabetes-16, GI disorders-41, migraine-
18). Using initial search terms, we would have captured
only two-thirds of the eligible studies in our PubMed
search (range 55%–83% by setting). By undergoing the
explorative process to identify additional terms, 90% of
studies (122/135, range 80–100% by setting) were iden-
tiﬁed via PubMed. CONCLUSIONS: Careful iterative
development of search terms should be a component of
all systematic searches in PubMed. Supplemental elec-
tronic and manual searching remains necessary to obtain
a comprehensive study set. PubMed indexing varies by
clinical setting and journal subject, with somewhat
weaker results for pharmacoeconomic/managed care
journals (78%) than disease-speciﬁc (94%) or general
medical (98%) journals.
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OBJECTIVE: To review the current state of economic
and outcomes research focusing on its application, rele-
vance and communication forums. METHODS: A review
of the literature, web sites and guidelines was performed
to identify examples where economic and outcomes
research was used. A literature search for the top 10
selling drugs in 2000 was also performed to evaluate the
extent of outcomes research in these products’ communi-
cations strategy. RESULTS: As of 2002, 9 countries
required pharmacoeconomic data in reimbursement deci-
sions, 14 countries had informal guidelines and 6 were
under development. Of the top 10 drugs by revenues,
several trends were noted: a decrease in outcomes com-
munication near patent expiration (e.g., omeprazole), a
focus on economic studies rather than PRO when cost
offset was a potential advantage (e.g., celecoxib), an
emphasis on communicating quality of life information
even when drug acquisition costs are high (e.g., epoetin
alpha), and a shift from economic communication, fol-
lowing successful formulary pull-through, to patient sat-
isfaction and quality of life. Internationally, the relevance
of PRO data may be increasing. New strategies for the
use of economic and outcomes data have also been found:
in a class of drugs for intermittent claudication facing a
revision of its reimbursement dossier in France, a positive
PRO study resulted in the change in the package insert
for one product, and that product was the only one its
class to regain market share; examples of the use of eco-
nomic data to avoid de-reimbursement also occurred in
France. Quality issues continue to be a problem in reim-
bursement submissions in several countries (notably 
Australia). CONCLUSION: Economic and outcomes
information is being used in an attempt to improve
market share by answering regulatory requests and in
limited instances may play a crucial role in preserving or
increasing revenues.
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OBJECTIVES: There is limited information on whether
pharmacoeconomic/outcomes research (PE/OR) fellow-
ship programs provide their trainees with an appropriate
set of skills. The objectives are to: 1) identify which
PE/OR skills are most commonly used by former fellow-
ship trainees in their current work setting, and 2) deter-
mine whether former fellowship program participants
ﬁnd their training applicable to their present occupation.
METHODS: A 41-item questionnaire was administered
to former fellows of PE/OR fellowship programs via the
ISPOR website. Former fellows were identiﬁed through
the directories of the American College of Clinical Phar-
macy and ISPOR as well as the website and membership
roll of ISPOR. Individuals were enrolled if they 1) com-
pleted a PE/OR program at least 3 months prior to initi-
ation of the survey, and 2) were currently employed.
RESULTS: Of the 61 respondents meeting the inclusion
criteria, 56% completed a PE/OR fellowship program
after 1999; 55% and 20% work in the pharmaceutical
industry and academia, respectively. Respondents spent
27% and 32% of their time performing PE and OR,
respectively. Respondents were actively involved in the
conceptualization (74%), operationalization (54%), and
data management (67%) of research projects. Overall,
90% of the respondents were satisﬁed with their PE/OR
fellowship experience, and 92% stated that the program
provided the necessary skills for their work setting. PE,
decision analysis and modeling, and OR were cited as the
most essential topics needed for their current occupation.
CONCLUSIONS: According to former fellows, it appears
that the current skill sets provided in PE/OR fellowship
programs prepare individuals for today’s work environ-
ment within the ﬁeld of PE/OR. These ﬁndings help
demonstrate that PE/OR fellowships are valuable train-
ing programs.
